147 related articles for article (PubMed ID: 2624062)
1. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.
Thalén A; Brattsand R; Andersson PH
Acta Derm Venereol Suppl (Stockh); 1989; 151():11-9; discussion 47-52. PubMed ID: 2624062
[TBL] [Abstract][Full Text] [Related]
2. Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion.
Scott M; Malmsten LA; Thelin I
Acta Derm Venereol; 1981; 61(6):543-6. PubMed ID: 6177167
[TBL] [Abstract][Full Text] [Related]
3. Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids.
Edsbäcker S; Andersson P; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1987; 15(3):412-7. PubMed ID: 2886320
[TBL] [Abstract][Full Text] [Related]
4. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids.
Brattsand R; Thalén A; Roempke K; Källström L; Gruvstad E
J Steroid Biochem; 1982 Jun; 16(6):779-86. PubMed ID: 7109581
[TBL] [Abstract][Full Text] [Related]
5. Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies.
Gomez EC; Kaminester L; Frost P
Arch Dermatol; 1977 Sep; 113(9):1196-202. PubMed ID: 332089
[TBL] [Abstract][Full Text] [Related]
6. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities.
Brattsand R; Thalén A; Roempke K; Källström L; Gruvstad E
Eur J Respir Dis Suppl; 1982; 122():62-73. PubMed ID: 6958495
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity.
Thalén A; Brattsand R
Arzneimittelforschung; 1979; 29(11):1687-90. PubMed ID: 543875
[TBL] [Abstract][Full Text] [Related]
8. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.
Dahlberg E; Thalén A; Brattsand R; Gustafsson JA; Johansson U; Roempke K; Saartok T
Mol Pharmacol; 1984 Jan; 25(1):70-8. PubMed ID: 6708937
[TBL] [Abstract][Full Text] [Related]
9. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
10. Metabolic pathways of the topical glucocorticoid budesonide in man.
Edsbäcker S; Jönsson S; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1983; 11(6):590-6. PubMed ID: 6140145
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis].
Lebrun-Vignes B; Legrain V; Amoric J; Taïeb A
Ann Dermatol Venereol; 2000; 127(6-7):590-5. PubMed ID: 10930856
[TBL] [Abstract][Full Text] [Related]
12. Prospects for future topical glucocorticoid development.
Brattsand R; Särnstrand B
Acta Derm Venereol Suppl (Stockh); 1989; 151():37-46; discussion 47-52. PubMed ID: 2624065
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological study of 9 alpha-fluoro-11 beta, 17, 21-trihydroxy-16 beta-methylpregna-1, 4-diene-3,20-dione-17-benzoate (betamethasone-17-benzoate, MS-1112), a local anti-inflammatory agent. (1). Its anti-inflammatory and other pharmacological properties].
Okada N; Okazaki Y; Wada I; Tanaka Y; Fukuda T
Nihon Yakurigaku Zasshi; 1975 Mar; 71(2):231-52. PubMed ID: 1169196
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluation of new topical anti-inflammatory steroids.
Sin KS; Lee HJ; Kim HP
Drugs Exp Clin Res; 1991; 17(8):375-80. PubMed ID: 1822829
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21-dipropionate in human liver and lung homogenate.
Andersson P; Ryrfeldt A
J Pharm Pharmacol; 1984 Nov; 36(11):763-5. PubMed ID: 6150981
[TBL] [Abstract][Full Text] [Related]
16. Topical application of potent glucocorticoids augments epidermal beta-adrenergic adenylate cyclase response in vivo.
Kajita S; Iizuka H; Hirokawa M; Tsutsui M; Mizumoto T
Acta Derm Venereol; 1986; 66(6):491-6. PubMed ID: 2433868
[TBL] [Abstract][Full Text] [Related]
17. Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson P; Lihné M; Thalén A; Ryrfeldt A
Xenobiotica; 1987 Jan; 17(1):35-44. PubMed ID: 3825176
[TBL] [Abstract][Full Text] [Related]
18. Problems in selection of topical anti-inflammatory corticosteroids.
Stewart WD; Runikis JO; Verma SC; Wallace S
Can Med Assoc J; 1973 Jan; 108(1):33-8. PubMed ID: 4682636
[TBL] [Abstract][Full Text] [Related]
19. Topical corticosteroid allergy in an urban Australian centre.
Keegel T; Saunders H; Milne R; Sajjachareonpong P; Fletcher A; Nixon R
Contact Dermatitis; 2004 Jan; 50(1):6-14. PubMed ID: 15059096
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of induction of human contact sensitization by topical glucocorticosteroids.
Burrows WM; Stoughton RB
Arch Dermatol; 1976 Feb; 112(2):175-8. PubMed ID: 962352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
